高级检索
当前位置: 首页 > 详情页

Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China [2]Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology,Shanghai, China [3]Department of Ophthalmology, Beijing Tongren Hospital, Capital MedicalUniversity, Beijing, China [4]Department of Ophthalmology, Beijing Children’s Hospital, CapitalMedical University, Beijing, China [5]Department of Interventional Radiology and Vascular Anomalies,Guangzhou Women and Children’s Medical Center, Guangzhou, China [6]Department of Ophthalmology, Xiangya Hospital, Central South University,Changsha, China [7]Department of Ophthalmology, Qilu Children’s Hospital of ShandongUniversity, Jinan, China [8]Department of Ophthalmology, Army Medical Center of PLA, Chongqing,China [9]Department of Ophthalmology, Kunming Children’s Hospital, Kunming,China [10]Department of Ophthalmology, Renmin Hospital of Wuhan University,Wuhan, China [11]Department of Ophthalmology, Hebei Children’s Hospital, Shijiazhuang,China [12]Department of Ophthalmology, Tangdu Hospital, The Fourth MilitaryMedical University, Xi’an, China [13]Department of Ophthalmology, Harbin Children’s Hospital, Harbin,China [14]Department of Ophthalmology, The First Affiliated Hospital of USTC(Anhui Provincial Hospital), University of Science and Technology ofChina, Hefei, China [15]Department of Ophthalmology, The Second Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, China [16]Department of Ophthalmology, Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China [17]Department of Ophthalmology, Children’s Hospital of Nanjing MedicalUniversity, Nanjing, China [18]Department of Ophthalmology, Second Provincial People’s Hospital ofGansu, Lanzhou, China [19]Department of Ophthalmology, The Second Hospital of Dalian MedicalUniversity, Dalian, China [20]Department of Ocular Trauma and Orbital Diseases, Affiliated EyeHospital of Nanchang University, Nanchang, China [21]Department of Ophthalmology, The Second Hospital of Jilin University,Changchun, China [22]Department of Ophthalmology, The Affiliated Hospital of InnerMongolia Medical University, Huhhot, China [23]Department of Ophthalmology, West China Hospital, Sichuan University,Chengdu, China [24]Department of Ophthalmology, Affiliated Shenzhen Eye Hospital of JinanUniversity, Shenzhen, China [25]Department of Ophthalmology, The People’s Hospital of GuangxiZhuang Autonomous Region, Nanning, China [26]Department of Ophthalmology, Tibet Autonomous Region Eye Center,Tibetan Medicine Hospital, Lhasa, China [27]Department of Ophthalmology, The General Hospital of Xinjiang MilitaryCommand of PLA, Urumchi, China [28]Department of Ophthalmology, Kashgar Prefecture Second People’sHospital, Kashgar, China [29]Department of Ophthalmology, Hainan Eye Hospital and Key Laboratoryof Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University,Haikou, China [30]Department of Ophthalmology, The Affiliated Hospital of GuizhouMedical University, Guiyang, China [31]Department of Ophthalmology, Tianjin Medical University Eye Hospital,Tianjin, China [32]Department of Ophthalmology, NingXia Eye Hospital, People’s Hospitalof Ningxia Hui Autonomous Region, Yinchuan, China [33]Department of Ophthalmology, Qinghai University Affiliated Hospital,Xining, China [34]National Center for Chronic and Noncommunicable Disease Control andPrevention, Chinese Center for Disease Control and Prevention, Beijing,China [35]Clinical Research Institute, Shanghai Jiao Tong University School ofMedicine, Department of Bioinformatics and Biostatistics, Shanghai JiaoTong University, Shanghai, China [36]Department of Ophthalmology, Peking University People’s Hospital,Beijing, China [37]Department of Ophthalmology, Henan Children’s Hospital, Zhengzhou,China [38]Department of Ophthalmology, Quanzhou Women’s and Children’sHospital, Quanzhou, China [39]Department of Ophthalmology, The General Hospital of Chinese People’sArmed Police Forces, Beijing, China [40]Department of Ophthalmology, Xinhua Hospital affiliated to ShanghaiJiao Tong University School of Medicine, Shanghai, China [41]Chuandi Zhou’s current affiliation is Department of Ophthalmology,Shanghai General Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai, China
出处:
ISSN:

关键词: Cohort study Enucleation Eye-preserving therapies Retinoblastoma

摘要:
This study attempted to estimate the impact of eye-preserving therapies for the long-term prognosis of patients with advanced retinoblastoma with regard to overall survival and ocular salvage.Retrospective cohort study covering all 31 provinces (38 retinoblastoma treating centers) of mainland China.One thousand six hundred seventy-eight patients diagnosed with group D or E retinoblastoma from January 2006 through May 2016.Chart review was performed. The patients were divided into primary enucleation and eye-preserving groups, and they were followed up for survival status. The impact of initial treatment on survival was evaluated by Cox analyses.Overall survival and final eye preservation.After a median follow-up of 43.9 months, 196 patients (12%) died, and the 5-year overall survival was 86%. In total, the eyeball preservation rate was 48%. In this cohort, 1172 patients (70%) had unilateral retinoblastoma, whereas 506 patients (30%) had bilateral disease. For patients with unilateral disease, 570 eyes (49%) underwent primary enucleation, and 602 patients (51%) received eye-preserving therapies initially. During the follow-up (median, 45.6 months), 59 patients (10%) from the primary enucleation group and 56 patients (9.3%) from the eye-preserving group died. Multivariate Cox analyses indicated no significant difference in overall survival between the 2 groups (hazard ratio [HR], 1.25; 95% confidence interval [CI], 0.85-1.84; P = 0.250). For patients with bilateral disease, 95 eyes (19%) underwent primary enucleation, and 411 patients (81%) received eye-preserving therapies initially. During the follow-up (median, 40.1 months), 12 patients (13%) from the primary enucleation group and 69 patients (17%) from the eye-preserving group died. For bilateral retinoblastoma with the worse eye classified as group E, patients undergoing primary enucleation exhibited better overall survival (HR, 2.35; 95% CI, 1.10-5.01; P = 0.027); however, this survival advantage was not evident until passing 22.6 months after initial diagnosis.Eye-preserving therapies have been used widely for advanced retinoblastoma in China. Patients with bilateral disease whose worse eye was classified as group E and who initially underwent eye-preserving therapies exhibited a worse overall survival. The choice of primary treatment for advanced retinoblastoma should be weighed carefully.Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 眼科学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 眼科学
第一作者:
第一作者机构: [1]Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China [2]Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology,Shanghai, China [41]Chuandi Zhou’s current affiliation is Department of Ophthalmology,Shanghai General Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China [2]Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology,Shanghai, China [4]Department of Ophthalmology, Beijing Children’s Hospital, CapitalMedical University, Beijing, China [5]Department of Interventional Radiology and Vascular Anomalies,Guangzhou Women and Children’s Medical Center, Guangzhou, China [40]Department of Ophthalmology, Xinhua Hospital affiliated to ShanghaiJiao Tong University School of Medicine, Shanghai, China [*1]Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhi Zao Ju Road, Shanghai 200011, China [*2]Department of Ophthalmology, Beijing Children’s Hospital, Capital Medical University, 56 South Lishi Road, Xicheng District Beijing, Beijing, 100045, China [*3]Department of Ophthalmology, Xinhua Hospital, Affiliated to Medicine School of Shanghai Jiaotong University, No. 1665, Kongjiang Road, Shanghai, 200092, China [*4]Department of Interventional Radiology and Vascular Anomalies, Guangzhou Women and Children’s Medical Center, No. 318 Renmin Road, Guangzhou, 510623, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号